R.The US Food and Drug Administration (FDA) no longer recommends the annual Covid-19 vaccines for children and most adults.
In the editorial An article published in New England Magazine for MedicineDr. Vinay Brasad, the newly appointed president of the Center for Biological Evaluation and Research in the FDA, and Dr. Martin Macari, Food and Drug Administration Commissioner (FDA), explained his plan for how to evaluate and recommends to the Covid-19 to recommend.
So far, the federal guidance recommended that each person receive six months or the largest Covid-19 vaccine targeting the latest virus’s most trading version to increase their chances of avoiding severe disease.
The New Food and Drug Administration Command still recommends that the groups at a risk of hospitalization or death from Covid-19 will receive the annual Covid-19 shots. This includes the elderly and adults with weak immune system and people with essential health conditions such as cancer. Some people in these groups may qualify for a second round in a specific year, depending on risk factors.
But for persons at risk, the FDA leadership (FDA) alternatively leads to additional studies to test whether people in the general population who get an annual shot have fewer COVID-19 symptoms, lower cases, and less hospitals and deaths compared to those who receive an imaginary drug. Pfizer-Biontech, Moderna and Novavax, which make Covid-19 vaccines, immediately ask for a comment on the changes.
“We simply do not know if a 52-year-old healthy woman has a regular body mass index that got Covid-19 three times and received six previous doses from the Covid-19 vaccine will benefit from the seventh dose,” Brasad and Makari wrote in the opening article. “This policy will force the generation of evidence that it is needed.”
Read more: How a child changes under Trump
Brasad and Makari writes that the proposed studies will not interfere with the current timetable for approval of the annual Covid-19 vaccines, as it will be done after the release of the vaccine, while the agency calls it post-marketing studies. Consultative Committee for Experts in Food and Drug Administration interview On May 22 to review data from the World Health Organization on the variables targeting in the upcoming season vaccine, which will be distributed in the fall.
Even if the additional studies are not delayed the availability of the next Covid-19th shot, it will put an additional burden on pharmaceutical companies to conduct another experience, which can add to the cost of the vaccine to the public, he says Dr. Paul OfitMember of the Football Food Consulting Committee and a professor at the Children’s Hospital in Philadelphia.
The other challenge is that in order to conduct this type of trial, some people will have to obtain an imaginary drug, and therefore they are likely to be less protected than Covid-19. “Anyone can pick up this virus, deposit the hospital and kill,” says Ofit. “We know that the vaccine is working and may save three million lives, and we know that the virus is still circulating and still causes harm.” Because of this continuous danger, he says it is not clear whether the Institutional Review Council – which holds all study designs that include human volunteers – will be considered an ethical experience.
OFIT admits that for most people who are not at risk of developing severe diseases, who now have at least one, if not several episodes of Covid-19, get an annual vaccine is “low, low bonus.” Studies from the Disease Control Center show that the snapshot reinforces antibodies that fight the virus for four to six months, providing strong protection against mild to mild diseases during that time, but then protection fades. Various immune cells and T -cells continue to protect against severe diseases, hospitalization, and death, and this is another reason to stay aware of the vaccine.
Even the shortest protection, it may be worth it to avoid the disease. He says: “Buy yourself from four to six months of protection from moderate to moderate diseases, which is not trivial,” especially since more data indicates that repeated attacks from Covid-19 can contribute to more intense and durable symptoms Coveyd long.
